NATICK, Mass.--(BUSINESS WIRE)--AffyImmune, a clinical-stage biopharmaceutical company committed to developing novel, first-in-class, affinity-tuned CAR T cell therapies, presented preclinical data on ...
A study led by Chinese radiologists at Peking University in Beijing has shown that positron emission tomography (PET) imaging of intercellular adhesion molecule-1 (ICAM-1) expression is a predictor ...
Should women take part in clinical trials in breast cancer? Issues and some solutions. ICAM-1 expression was negative (-) in 14 patients (20%), weak (+) in 21 (30%), positive (++) in 30 (43%), and ...
NATICK, Mass., April 28, 2025 /PRNewswire/ -- AffyImmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, today announced an abstract detailing its affinity-tuned CAR T therapy AIC100 ...
First report to show link between GDF-15 and LFA-1/ICAM-1 cell adhesion axis in cancer, resulting in impaired infiltration of T cells into the tumor microenvironment First report to show link between ...
Presentation characteristics, risk profiles and long-term outcomes in a public health system, minority patient population with diffuse large B-cell lymphoma No significant financial relationships to ...
A new chimeric antigen receptor (CAR) T cell therapy called AIC100, which targets the ICAM-1 protein, demonstrated encouraging responses and an acceptable safety profile in patients with two types of ...
This is a preview. Log in through your library . Abstract Intercellular adhesion molecule-1 (ICAM-1) on the surface of cultured umbilical vein and saphenous vein endothelial cells was upregulated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results